Company profile: Sapience Therapeutics
1.1 - Company Overview
Company description
- Provider of novel peptide therapeutics addressing major unmet medical needs, including ST101, a peptide antagonist targeting C/EBPβ in Phase 2 for advanced solid tumors such as recurrent GBM, and ST316, a first-in-class peptide antagonist of β-catenin entering Phase 1-2 for solid tumors with Wnt/β-catenin pathway abnormalities.
Products and services
- Advancing Novel Therapeutics: A preclinical-stage initiative advancing novel therapeutics for major unmet medical needs, aligned with the company’s biotechnology focus and mission
- ST316: A first-in-class peptide antagonist of β-catenin entering Phase 1-2 clinical trials for treating solid tumors with Wnt/β-catenin pathway abnormalities
- ST101: A Phase 2-evaluated peptide antagonist targeting C/EBPβ for the treatment of advanced solid tumors, including recurrent GBM, in ongoing clinical studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sapience Therapeutics
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Acetylon
HQ: United States
Website
- Description: Provider of small molecule drugs aimed at realizing the therapeutic potential of histone deacetylase; incorporated in 2008 and based in Boston, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acetylon company profile →
Immunomic Therapeutics
HQ: United States
Website
- Description: Provider of lysosomal associated membrane protein-based immunotherapies and vaccines via its UNITE platform, leveraging natural biochemistry to elicit broad immune responses. Pipeline includes ITI-1000 (autologous dendritic cell therapy for glioblastoma), ITI-1001 (off-the-shelf CMV-targeting GBM immunotherapy), ITI-3000 (plasmid DNA vaccine for Merkel cell carcinoma), ITI-1771 (for CMV-driven cancers), and ITI-5000 (saRNA vaccine for TNBC).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunomic Therapeutics company profile →
Arc Medical
HQ: United Kingdom
Website
- Description: Provider of award-winning, innovative medical products designed to increase Adenoma Detection Rates (ADR) and improve retrieval methods, focusing on enhancing physician experience and patient outcomes with cost effectiveness.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arc Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sapience Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sapience Therapeutics
2.2 - Growth funds investing in similar companies to Sapience Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sapience Therapeutics
4.2 - Public trading comparable groups for Sapience Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →